Jobs Go At Shield Therapeutics As Failed Study Fallout Hits

Shield Therapeutics is to slash its workforce and is considering a possible sale in the wake of a failed Phase III study for its only marketed product, Ferracru, that should have given it access to the US market.

Warrior — Defensive Shield • Source: Shutterstock

Shield Therapeutics PLC is to make significant cuts to its workforce while its board considers the firm's future in light of the recent failure of a key new study of its only marketed drug Feraccru (ST10, ferric maltol) that would have opened it up to the US market.

The news comes just as the CHMP has voted to broaden the product's label in the EU, but as the...